Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study
Open accessAbstract
Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5‐HT 2A R) agonist psilocybin. However, no studies have investigated whether 5‐HT 2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy individuals (53 females), the association between 5‐HT 2A R binding in neocortex imaged with [18 F]altanserin or [11 C]Cimbi‐36 PET and personality trait Openness was investigated using linear regression models. In these models the influence of sex on the association was also investigated. Trait Openness was assessed with the NEO Personality Inventory‐Revised. No significant associations between neocortical 5‐HT 2A R binding and trait Openness were found for [18 F]altanserin (p = 0.5) or [11 C]Cimbi‐36 (p = 0.8). Pooling the data in a combined model did not substantially change our results (p = 0.4). No significant interactions with sex were found (p > 0.35). Our results indicate that differences in 5‐HT 2A R availability are not related to variations in trait Openness in healthy individuals. Although stimulation of the 5‐HT 2A R with compounds such as psilocybin may contribute to long‐term changes in trait Openness, there is no evidence in favor of an association between 5‐HT 2A R and trait Openness.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
At baseline in healthy individuals, there was no significant association between the trait for openness to experience and 5HT2A availability, measured with the antagonist [18F]altanserin or the agonist [11C]-Cimbi-36.
“At baseline in healthy individuals, at least, there was no significant association between the trait for openness to experience with 5HT2A availability, either measured with the antagonist [18F]altanserin (39), or with the agonist ([11C]-Cimbi-36 (38) [107].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [107]
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · see citing works
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1× · see citing works
“Psilocybin is a naturally occurring prodrug of psilocin, a serotoner- gic psychedelic produced by psilocybin mushrooms which shows promise as a novel therapeutic drug (Bogenschutz et al., 2015; Hum Brain Mapp.”
BackgroundPilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2× · see citing works
“…al., 2016) and is known to induce highly meaningful and, occasionally, mystical-type experiences (Baumeister, Barnes, Giaroli, & Tracy, 2014; Griffiths et al., 2011; Griffiths et al., 2016; Griffiths, Richards, McCann, & Jesse, 2006; Johnson et al., 2014; MacLean et al., 2011; Ross et al., 2016).”
BackgroundA High-Resolution<i>In Vivo</i>Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368 · see citing works
Self-citationBouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · see citing works
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · see citing works
Psychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183 · see citing works
Self-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69 · see citing works
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43 · see citing works
- Authors
- Stenbæk, D. S., Kristiansen, S., Burmester, D., Madsen, M. K., Frokjaer, V. G., Knudsen, G. M., & Fisher, P. M.
- Affiliations
- Rigshospitalet (DK)
- Neurobiology Research Unit Rigshospitalet Copenhagen Denmark
- ORCID
- Venue
- Human Brain Mapping
- Publisher
- Wiley
- Published
- 2019-01-11
- Volume
- 40
- Issue
- 7
- Pages
- 2117-2124
- ISSN
- 1065-9471 (ISSN-L)
- 1097-0193
- PMC
- PMC6865516
- OpenAlex
- W2909396647
- Cited by
- 11
- References
- 9
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 2
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Brain Mapping (publishedVersion)
- PubMed Central (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Lundbeckfonden (R62-2010-5364, R90-2011-7722)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- 5-HT2A receptor, psilocybin, personality traits, [18F]altanserin, neocortex, sex differences, healthy volunteers
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Brain, Female, Humans, Male, Middle Aged, Personality, Personality Inventory, Receptor, Serotonin, 5-HT2A, Positron-Emission Tomography, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
